Automated technology for safe home management of heart rhythm medications
Official title: Novel, automated mobile heart rhythm analysis technology to start antiarrhythmic medications safely at home
Funded at Safebeat Rx INC. · NIH-10815458 · Data updated 2026-11-12
This study is testing a new mobile technology that helps people with atrial fibrillation start heart medications safely at home, making it easier for those who may not have easy access to doctors or hospitals.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Safebeat Rx INC. NIH-funded |
| Lab location | 1 site (Carson, UNITED STATES) |
| Project start | July 19, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $994,131 |
| NIH project number | 1R44HL167294-01A1 |
| Project ID | NIH-10815458 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with atrial fibrillation who require antiarrhythmic medications and are at low risk for heart rhythm complications.
✕Less likely to help
Patients who do not have atrial fibrillation or those who are at high risk for complications from antiarrhythmic medications may not benefit from this research.
What this research studies
This research focuses on developing a novel mobile technology that enables patients with atrial fibrillation (AF) to safely start antiarrhythmic medications at home. The approach involves using a combination of a mobile ECG device, cardiac telemetry, and wearable defibrillator, along with proprietary software to monitor heart rhythms. By automating the measurement of QTc intervals from ECGs, the technology aims to reduce the need for hospitalization, which is currently required to initiate these medications due to potential side effects. This is particularly beneficial for patients in rural or underserved areas who may have limited access to healthcare facilities.
Why it matters
Potential benefit: If successful, this research could significantly improve access to life-saving heart rhythm medications for patients with atrial fibrillation, enhancing their quality of life and reducing hospital visits.
How similar studies have gone: Previous research has shown promise in using mobile technology for heart monitoring, indicating that this approach could be effective in improving patient outcomes.
Where this research is happening
-
Safebeat Rx INC.
Carson, United States Active
Researchers
- Principal investigator: Navara, Rachita — Safebeat Rx INC.
- Study coordinator: Navara, Rachita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.